Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies

 
• By Joseph Haas

Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease

GI disease
Takeda keeps investing in celiac disease as part of its GI therapy focus • Source: Shutterstock

More from Deals

More from Business